GI
NBIX icon

GAMMA Investing’s Neurocrine Biosciences NBIX Stock Holding History

GAMMA Investing’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$626K Buy
3,714
+868
+30% +$129K 0.02% 552
2026
Q1 		$375K Sell
2,846
-198
-7% -$26.3K 0.02% 717
2025
Q4 		$432K Buy
3,044
+358
+13% +$51.9K 0.02% 590
2025
Q3 		$377K Buy
2,686
+331
+14% +$44.8K 0.02% 609
2025
Q2 		$296K Buy
2,355
+374
+19% +$42.9K 0.02% 680
2025
Q1 		$219K Sell
1,981
-314
-14% -$39.8K 0.02% 719
2024
Q4 		$313K Buy
2,295
+557
+32% +$68.9K 0.03% 526
2024
Q3 		$200K Buy
1,738
+185
+12% +$25.4K 0.02% 624
2024
Q2 		$214K Buy
1,553
+395
+34% +$54.2K 0.03% 479
2024
Q1 		$160K Buy
1,158
+310
+37% +$42.3K 0.03% 470
2023
Q4 		$119K Buy
+848
New +$97.6K 0.03% 477

Other funds holding NBIX

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
PBBUPS
PKO BP Bankowy Universal Pension Society Warsaw, Poland $350M AUM 272.18% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
AB
Amalgamated Bank New York $14.5B AUM 44.3% 1-Year Est. Return

GAMMA Investing's NBIX Position: Q2 2026 in Review

GAMMA Investing increased its Neurocrine Biosciences (NBIX) stake by 30% in Q2 2026, buying an estimated $129K and bringing the position to 3,714 shares worth $626K. The position accounts for 0.02% of the portfolio, ranked #552.

GAMMA Investing first reported a position in NBIX in Q4 2023 and has held it in 11 quarters since. 166 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • GAMMA Investing held 3,714 shares of Neurocrine Biosciences worth $626K as of Q2 2026.
  • GAMMA Investing bought 868 Neurocrine Biosciences shares in Q2 2026, an estimated $129K.
  • Neurocrine Biosciences made up 0.02% of GAMMA Investing's portfolio in Q2 2026, its #552 holding.
  • GAMMA Investing first reported a position in Neurocrine Biosciences in Q4 2023 and has held it in 11 quarters since.
  • 166 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.